TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Sees Large Decline in Short Interest

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 9,400 shares, a decline of 15.3% from the March 31st total of 11,100 shares. Based on an average daily trading volume, of 7,300 shares, the short-interest ratio is currently 1.3 days.

Institutional Trading of TriSalus Life Sciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Clear Street LLC purchased a new stake in TriSalus Life Sciences in the 4th quarter valued at about $60,000. Context Capital Management LLC purchased a new stake in TriSalus Life Sciences in the 3rd quarter valued at about $27,000. Shaolin Capital Management LLC purchased a new stake in TriSalus Life Sciences in the 3rd quarter valued at about $29,000. Wolverine Asset Management LLC purchased a new stake in TriSalus Life Sciences in the 4th quarter valued at about $123,000. Finally, MSD Partners L.P. acquired a new position in TriSalus Life Sciences in the 3rd quarter valued at about $51,000.

TriSalus Life Sciences Stock Performance

Shares of TLSIW opened at $0.99 on Monday. TriSalus Life Sciences has a 12-month low of $0.02 and a 12-month high of $1.35. The company’s 50-day moving average price is $1.04 and its 200 day moving average price is $0.78.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.